Greenwich LifeSciences, Inc.
GLSI Nasdaq· Pharmaceutical Preparations
Last close · Oct 26, 2026
$17.13
KIRA · Stoqly’s AI analyst, in plain words
- Greenwich LifeSciences, Inc. lost $19.4M in fiscal 2025.
Market cap
$250M
P/E
—
Revenue
—
Net income
−$19.4M
Free cash flow
—
Operating margin
—
Greenwich LifeSciences, Inc. in 30 seconds · fiscal 2025
Does it make a profit?
−$19.4M
No. It lost money last year.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Greenwich LifeSciences, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Jun 1, 2026
- Legal name
- Greenwich LifeSciences, Inc.
- CIK
- 0001799788
Greenwich LifeSciences, Inc. · GLSI
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Net income | −$4.6M | −$7.8M | −$8.9M | −$17.4M | −$19.4M |
| Diluted EPS | −$0.35 | −$0.61 | −$0.69 | −$1.34 | −$1.43 |
| Cash | |||||
| Cash from operations | −$4.3M | −$6.2M | −$6.5M | −$7.3M | −$9.9M |
| Share buybacks | — | $7.5M | — | — | — |
| Share count change | 36.3% | −0.2% | −0.5% | 1.3% | 4.0% |
| Debt and strength | |||||
| Cash and short-term investments | $27.2M | $13.5M | $7.0M | $4.1M | $6.2M |
| Shareholders' equity | $26.8M | $13.2M | $6.7M | $0.9M | $0.4M |
| Current ratio | — | — | — | 1.3x | 1.1x |
| Returns and quality | |||||
| Return on equity | −16.8% | −39.1% | −89.3% | −457.7% | −3,068.3% |
| Return on tangible equity | −17.0% | −59.3% | −132.8% | −1,920.4% | −5,480.8% |
| Altman Z'' | — | — | — | −81.2 | −66.7 |
Insiders bought, 12 months
$0.6M
1 insider
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Greenwich LifeSciences, Inc. · GLSI
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $17.13 a share, the company is worth $250M.
Source: SEC EDGAR XBRL filings (CIK 0001799788). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.